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Brain growth factors are a broad group of molecules that enable the brain to adapt to
stress. In a study on Alzheimer’s mice (APP), we tested the role of an asparagus
supplement, ETAS®50, to mitigate the stress caused by the Alzheimer’s condition in this
mouse model. Gene expression data revealed regulation of genes related to neuronal
growth and function, such as tau, which were severely stressed in the APP mice to be
alleviated.
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CHAPTER 1 – Introduction
1.1 Background Information
Neurodegenerative diseases (ND) are a group of diseases denoted by a gradual
loss of function in neurons, synapses, glial cells, and their associated structures. The
deposition of physiological proteins that are physiochemically altered in both neurons
and glial cells are hallmark elements of NDs. NDs are classified by the way they present
clinically, the anatomical regions and cell types affected, the altered proteins involved in
pathogenesis, and, if known, the etiology of the disease (Kovacs, 2019). Hundreds of
NDs affect millions of people across the globe, highlighting the need for more research to
find a cure for these diseases (Neurodegenerative Diseases 2021; Neurodegenerative
Diseases 2022). Unfortunately, at this time, the only treatments exist to help alleviate the
symptoms of NDs, but there are no therapies to help slow the disease’s progression
(Neurodegenerative Diseases 2022).
When classifying NDs based on their clinical symptoms, it is essential to note that
the anatomical region affected, and not necessarily the modified protein that is
distributed, determines the clinical signs. NDs present clinically as either a decline in
higher-order functions, issues with movement, or a variation of both (Kovacs, 2019).
Classifying NDs solely by their clinical presentation presents its own set of challenges.
The same ND can affect multiple regions of the brain, causing the symptoms to present
differently in each case of that ND. Although clinical classification presents these
problems, it is still the most popular method of ND categorization, along with identifying
predominant lesions on the surface of the affected anatomical region or cells (Przedborski
et al., 2003).
1
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Anatomically, NDs can be divided into primary categories based on the brain
region affected: cerebral cortex, basal ganglia, cerebellum and brainstem, or spinal cord.
These primary groups can be further subdivided.
NDs affecting the cerebral cortex are subdivided into diseases exhibiting dementia
or non-dementia exhibiting disorders. Dementia is not limited to only NDs; it is also a
result of toxic, metabolic, infectious, ischemic, and traumatic events that occur in the
brain.
A group of subcortical nuclei located at the base of the forebrain called the basal
ganglia is affected by NDs. Those NDs can be classified by their abnormal movement
types: hypokinetic and hyperkinetic movements. Patients with hypokinetic movements
have decreased or no ability to control voluntary movements. On the other hand,
individuals with hyperkinetic movements experience tremors and immoderate abnormal
movements.
In the cerebellum and brainstem, most NDs are classified into three main groups
based on the location of lesions: cerebellar cortical atrophy, pontocerebellar atrophy, and
Friedreich ataxia, but several NDs can’t be categorized by this grouping system.
Cerebellar cortical atrophy NDs are characterized by a lesion that affects the Purkinje
cells and the inferior olives. A lesion that affects multiple brain and cerebellar structures
is a hallmark of pontocerebellar atrophy NDs. NDs that occur because of a lesion in the
posterior column of the spinal cord, peripheral nerves, and the heart as classified as
Friedreich ataxia.
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Like Friedreich ataxia, NDs that mainly affect the spinal cord are characterized
by severe lesions to the spinal cord. Still, in spinal cord NDs, the lesions are to the
anterior portion of the spinal cord. In addition, a particular group of NDs is often not
characterized as NDs due to their unknown etiology and chronic course. They also do not
exhibit any apparent structural abnormalities. These special NDs include but are not
limited to Tourette syndrome, schizophrenia, torsion dystonia, and essential tremor
(Przedborski et al., 2003).
NDs can also be classified by accumulating physiochemically altered proteins in
intracellular, extracellular, and synaptic spaces. Amyloid-beta (Aβ), microtubuleassociated protein tau (tau), α-synuclein (α-syn), and brain-derived neurotrophic factor
(BDNF) are proteins that are associated with either random or genetic-related agedependent NDs. Aβ is a 770 amino acid protein encoded by the amyloid precursor protein
(APP) gene found on chromosome 21q21.3 (Kovacs, 2019). The extracellular deposition
of this protein results in NDs referred to as amyloidoses (Dugger & Dickson, 2017).
Amyloidoses are neurodegenerative diseases caused by extracellular deposits of insoluble
fibrous proteins that form plaques in the brain parenchyma or amyloid angiopathy in the
blood vessels. There are several different amyloid plaque morphologies: diffuse, densecored, classical, and cotton wool. Each variation is specific to where the protein is
deposited neuroanatomically, the disease’s stage, and the amyloid species. Aβ is the most
common amyloidosis. This amyloid protein is found in the brain and is a comorbid
characteristic of NDs that affect the elderly population (Dugger & Dickson, 2017).
Alzheimer’s disease (AD) is a type of dementia that affects a person’s memory, intellect,
and personality. It results from depositing multiple physiochemically altered proteins: Aβ
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and neuronal tau. In AD, the levels of the Aβ protein are dysregulated, leading to the
deposition of Aβ senile plaques that can interact with several different receptors causing a
disruption in normal neuronal functions (Sadigh-Eteghad et al., 2014). The accumulation
of Aβ senile plaques paired with the tau protein neurofibrillary tangles leads to the
pathogenesis of AD, a mixed proteinopathy. (Dugger & Dickson, 2017).
Tau, a protein encoded by the microtubule-associated protein tau gene located on
chromosome 17q21, predominantly deposits into the intracellular space of cells and is
responsible for the NDs categorized as tauopathies (Dugger & Dickson, 2017; Kovacs,
2019). tauopathies are NDs that result from an abnormal aggregation in neurons and glial
cells. These diseases can be divided into two categories: primary and secondary. Primary
tauopathies are diseases that NDs where tau is the major contributor to neurodegeneration
in conditions such as Richardson’s syndrome and corticobasal syndrome. Diseases where
tau is a co-factor in neurodegeneration’s pathogenesis, such as Alzheimer’s and Lewy
body disease, are secondary tauopathies. (Dugger & Dickson, 2017; Josephs, 2017).
Richardson syndrome (RS) is a type of progressive supranuclear palsy characterized by
gait problems, balance issues, cognitive decline, and problems with sight and eye
movement (Progressive Supranuclear Palsy (PSP): Treatments, signs & symptoms). The
aggregation of the 4R tau isoform in the subthalamic nucleus, substantia nigra, superior
colliculus, and cerebellar dentate leads to globose NFTs, tufted astrocytes,
oligodendroglial coiled bodies, and neuropil threads lead to the pathogenesis of RS
(Dugger & Dickson, 2017). Another primary tauopathy, corticobasal syndrome, results
from 4R tau isoform aggregates leading to pretangles, astrocytic plaques, neuropil
threads, and ballooned neurons in the frontoparietal association cortices, neostriatum, and
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substantia nigra (Dugger & Dickson, 2017). Corticobasal syndrome is a rare ND that
affects one’s ability to walk and talk as the disease progresses (Corticobasal
degeneration: Symptoms, causes, treatment & outlook). AD, classified as a secondary
tauopathy, is the result of both Aβ and 3R+4R tau aggregating in the basal forebrain,
frontal and temporal lobes, limbic structures, locus coeruleus, and the olfactory bulb
leading to neurofibrillary tangles, neuropil threads, neuritic and amyloid plaques, and
amyloid angiopathy. These multi-protein aggregations are responsible for the hallmark
symptoms associated with AD, such as dementia. The second most common form of
dementia, Lewy body dementia (LBD), is also classified as a secondary tauopathy
(Josephs, 2017; Lewy body dementia, 2021). Lewy body dementia results from the
accumulation of both α-syn and tau in the LBD pathology, leading to Lewy bodies and
Lewy neurites (Dugger & Dickson, 2017).
Encoded by the SNCA gene located on chromosome 4, α-syn is a 140 amino acid
protein deposited into the intracellular spaces and responsible for a series of NDs called
synucleinopathies (Dugger & Dickson, 2017; Kovacs, 2019). Multiple system atrophy
(MSA) is a rare ND that affects a person’s autonomic nervous system and movement
(Multiple system atrophy: Medlineplus genetics 2016). Glial cytoplasmic inclusions form
because α-syn is deposited in the putamen, substantia nigra, pontine nuclei, medulla, and
cerebellum leading to the pathogenesis of MSA (Dugger & Dickson, 2017).
BDNF, an extracellularly deposited protein, is a 247 amino acid protein encoded
by the brain-derived neurotrophic factor gene on chromosome 11p14.1, which promotes
the survival of neurons in the adult brain (Bathina & Das, 2015; Database, BDNF).
BDNF can improve synaptic plasticity and influence the formation of new neurons in the
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brain. In several NDs, including Huntington’s disease and Parkinson’s disease, the levels
of BDNF are decreased, suggesting that BDNF plays a role in preventing ND pathology
(Bathina & Das, 2015).
1.2 Research Motivation
NDs affect millions of people worldwide, and effective therapies must be
developed to help either cure individuals of their ND or to help drastically slow the
progression of the disease (Przedborski et al., 2003). Currently on the market are drugs
that treat an individual’s symptoms, not the disease. More research must be conducted to
better understand how neurodegeneration occurs in the different NDs to create effective
therapies for NDs (Neurodegenerative Diseases; Przedborski et al., 2003).
To identify the neuroprotective effects of an ETAS®50 (an extract derived from
Asparagus officinalis stems) on heat shock proteins, Peng et al. conducted an experiment
using APP-overexpressing transgenic mice which have the mutation associated with
early-onset AD. The mice were fed an ETAS®50, and their cognitive function was
measured using the Morris Water Maze (MWM). After the experiment, the mice were
euthanized, and their RNA was extracted and purified to create an Agilent Gene Array
(Peng et al., 2021). This experiment aims to understand the neuroprotective effects of
ETAS®50 on critical proteins associated with neuropathogenesis, such as Aβ, tau, α-syn,
and BDNF.

CHAPTER 2 – Literature Review
Neurodegeneration
Neurodegenerative diseases (NDs) result from the progressive deterioration of
neurons, synapses, glial cells, and other supporting anatomical structures in the nervous
system (Kovacs, 2019). As these structures begin to malfunction or die, the individual
begins to experience the early symptoms of the corresponding ND. Still, as the disease
progresses, the person starts to experience symptoms that affect their everyday life, such
as a decline in cognition, aphasia, apraxia, or loss of the ability to perform executive
functions, and eventually death due to many of these diseases being fatal (Brown et al.,
2005; The Challenge of Neurodegenerative Diseases,
https://neurodiscovery.harvard.edu/challenge).
Regarding neurodegeneration, there are many risk factors, but aging significantly
influences one’s chances of being diagnosed with one of the many NDs. Therefore, as the
US population ages, more research must be done to identify the mechanisms causing NDs
and discover new treatments or therapies that will either prevent or slow the progression
of NDs. The US population aged 65+ is estimated to expand from 53 million to 88
million by 2050. Without effective therapies, the US will continue to funnel billions of
dollars into healthcare for neurodegenerative diseases (Brown et al., 2005).
Neurodegenerative diseases result from physiochemically altered proteins
aggregating in brain regions leading to cognitive decline. Most NDs are multiproteinopathies, and their pathogenesis is characterized by the deposition of multiple
essential proteins (Dugger & Dickson, 2017). For example, hallmark characteristics of
AD include the presence of Aβ plaques and tau neurofibrillary tangles. Therefore,
7
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understanding the pathogenic mechanisms behind crucial proteins that contribute to
neurodegeneration is vital such as tau, alpha-synuclein, amyloid beta, and brain-derived
neurotrophic factor.
Microtubule-Associated Protein tau
The microtubule-associated protein tau (Mapt) gene is a protein-coding gene
located on chromosome 17. This gene contains approximately sixteen exons and occupies
a space of over 100kb. The protein encoded by this gene is called microtubule-associated
protein tau, mainly expressed in neurons. The tau protein is characterized as a
hydrophilic, asymmetrical protein that is randomly coiled. This protein can be divided
into the projection domain and the microtubule-binding domain. The projection domain is
the largest, and it contains approximately 67% of the molecule, and this domain can be
subdivided into two additional categories: the amino-terminal region and the proline-rich
region. The roles of the projection domain include mediating the spacing between axonal
microtubules, associations with other cytoskeletal proteins, and binding to cations. The
microtubule-binding domain comprises roughly 33% of the molecule, subdivided into the
true tubulin-binding region and the acidic carboxy-terminal region.
The tau protein can undergo several post-translational modifications such as
phosphorylation, glycosylation, ubiquitination, deamidation, oxidation, nitration, crosslinking, or glycation. Changes in the structure or amount of tau can lead to issues with the
stability of microtubules. These microtubule stability issues resulting from tau
modifications can affect other subcellular structures (mitochondria, lysosomes, etc.) that
could ultimately lead to the pathogenesis of tauopathies. A tauopathy is a pathological
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disease resulting from abnormal tau levels, abnormal phosphorylation and splicing of tau,
or mutations in the MAPT gene (Avila et al., 2004).
Alpha-Synuclein
The SNCA gene is located on the long arm of chromosome 4 and is composed of
six exons, and it encodes the alpha-synuclein (α-syn) protein (Avila et al., 2004; Bendor
et al., 2013). Alpha-synuclein is a small, acidic, 140 amino acid protein expressed in the
brain and is also found in Lewy bodies. The function of α-syn is to regulate the release of
neurotransmitters.
There are three domains present in this protein: N-terminal lipid-binding α-helix,
amyloid-binding central domain, and the C-terminal acidic tail. Residues 1-87 comprise
the positively charged N-terminal domain. The N-terminus contains 11 amino acid
repeats of a highly conserved hexametric motif (KTKEGV) that contributes to α-syn’s
ability to disrupt lipid bilayers. The amyloid-binding central domain, located in residues
61-95, functions in the formation and aggregation of fibrils. Finally, the C-terminal
domain, situated in residues 96-140, is the acidic tail of α-syn, and it can be
phosphorylated at multiple sites. However, it is the least conserved domain across both
species and the synuclein family, and the function of this region is not well understood
(Emamzadeh; Bendor et al., 2013).
Abnormal α-syn deposits – Lewy bodies – affects the brain’s chemical makeup
leading to a decline in cognition, behavior and personality changes, and movement
issues. Approximately 60% of all AD cases have Lewy pathology associated with them.
Alpha-synuclein is also associated with AD due to evidence of the amyloid-binding
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central domain being found at high levels in the cytoplasm of AD patients as senile
plaques (The Challenge of Neurodegenerative Diseases,
https://neurodiscovery.harvard.edu/challenge).
Brain-derived Neurotrophic Factor
The brain-derived neurotrophic factor (BDNF) gene, located on chromosome 11,
is a protein-coding gene that encodes for the protein BDNF (Database, BDNF). BDNF
comprises an initiation codon followed by a non-covalently linked homodimer with a
signal peptide and an N-linked glycosylation site (Bathina & Das, 2015). This 247amino-acid-protein shares 50% of its amino acid identity with other members of the
neurotrophin family of growth factors (Database, BDNF; The Challenge of
Neurodegenerative Diseases, https://neurodiscovery.harvard.edu/challenge). This
neurotrophic protein plays a role in neuronal growth, differentiation, and cell
maintenance (Database, BDNF). BDNF also plays a role in regulating synapses’
plasticity, which is needed for memory and learning. In addition, this protein is found in
the brain in regions that deal with eating, drinking, and body weight (Kovacs, 2019).
In AD patients, the BDNF levels are decreased by Aβ interactions. Aβ has been
associated with the direct inhibition of pro-BDNF being converted to BDNF and
indirectly interfering with the axonal transport of the BDNF-TrkB complex. A decline in
the levels of BDNF is characterized by the loss of synapses and neurons, age-associated
cognitive impairments, and AD (Tanila, 2017).

CHAPTER 3 - Materials & Methods
ETAS®50
ETAS®50 is an enzyme-treated asparagus extract supplement manufactured by
Amino Up Chemical Co., Ltd. in Sapporo, Hokkaido, Japan (Nishizawa et al., 2016).
First, Asparagus officinalis stems were boiled in 121ºC water for 45 minutes (Shirato et
al., 2018). After boiling, a cellulase, sucrase C (Mitsubishi-Kagaku Foods Corporation,
Tokyo, Japan), was added to the asparagus extract for 1.5 hours at 60°C. After adding the
cellulase, a pectinase called macerozyme A (Yakult Pharmaceutical Industry Co., Ltd,
Hyogo, Japan) was added at 45°C for 24 hours. Once the enzymes were inactivated
(121°C for 20 mins), the solution was centrifuged, and the supernatant was collected.
Next, the supernatant was mixed with dextrins (PINE-DEX; Matsutani Chemical Industry
Co., Ltd., Hyogo, Japan) in a 1:1 ratio by weight (Nishizawa et al., 2016; (Peng et al.,
2021). Then, the elemental ETAS®50 and dextrin solution were sterilized in a vacuum
for 45 mins at 121°C. After the sterilization, the solution was spray-dried to create a
powder form (Nishizawa et al., 2016).
Gene Array Analysis
Using the RNeasy microarray tissue mini kits from Qiagen (Germantown, MD),
total RNA was extracted from the hippocampal tissues of the 50 mice used in the Peng et
al. experiment. Then, the total RNA was cleaned using Life Technologies/Thermo Fisher
Scientific’s TURBO DNase (Grand Island, NY). RNA purity was then measured by the
NanoDrop 2000c spectrophotometer at absorbances of OD260/280 and OD260/230
(Thermo Fisher Scientific, Waltham, MA). Using the Bioanalyzer 2100 by Agilent
Technologies (Santa Clara, CA), the integrity of the RNA was analyzed. Samples with an
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RNA integrity number less than 6 were not processed in the microarray. Low input quick
amp one-color labeling kits (Agilent Technologies, Santa Clara, CA) were used to
amplify and label the 150ng of RNA that was converted to cDNA by following the
protocol from the manufacturer. Of the labeled cDNA, 1.65 μg was hybridized using
single-color mouse (V2) gene expression 4x44 K slides (Agilent Technologies, Santa
Clara, CA). The arrays were preprocessed and photographed using Agilent’s SureScan
and Feature Extraction software. The data background was corrected using the Feature
Scan software algorithms. Version 4.1 of BRB Array tools was used for subsequent
analysis. The normalization of the samples was achieved by qsSuantile normalization.
Transcripts with a minimum of 1.2-fold across groups were identified at p < 0.001, and
the Bonferroni test was used for correction. Further analysis was done for cases that
appeared to be significantly different from the rest using Qiagen Bioinformatics’
Ingenuity Pathway Analysis (Redwood City, CA, USA) (Peng et al., 2021). The gene
microarray data were transferred to Microsoft Excel, where it was mined, and the fold
change was calculated using the following formula: 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2 (𝑤𝑤𝑤𝑤𝑤𝑤ℎ 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸)

𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1 (𝑤𝑤𝑤𝑤𝑤𝑤ℎ𝑜𝑜𝑜𝑜𝑜𝑜 𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸)

.

String Analysis

The STRING database was searched using proteins known to be associated with
neurodegeneration: (Aβ), tau, α-syn, and BDNF to identify possible protein-protein
interactions. The STRING database collects information from scientific publications,
algorithms that predict computational interactions, and direct experiments. This
information is then scored and combined with other scores to create a final score
indicative of STRING’s confidence in the biological significance of the protein-protein
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interaction. The channels are scored independently and combined to create a final
combined score. The neighborhood channel’s score is based on the proximity of encoding
genes to one another on a chromosome, and the closer the genes, the higher the score.
Next, the fusion channel’s score is based on open reading frames that give insight into
possible gene-fusion events. The score is directly proportional to STRING’s ability to
delineate the genes of interest’s orthologs. In the co-occurrence channel, scores are given
by identifying similarities in the occurrence patterns of genes. The co-expression channel
assigns its score by comparing similarities in gene expression profiles. Protein-protein
interaction data is collected from genetic, biophysical, and biochemical experiments, and
this information is scored by the experiments channel. The knowledge channel uses
curated pathway databases to scan protein association data for its channel score.
Published scientific literature is automatically text mined to analyze statistical cooccurrence in the text mining channel to generate a score that will contribute to the
combined final score (Szklarczyk et al., 2020). Once a score is assigned, the combined
final score is saved to the database, and users can search using their protein(s) of interest
to see any association networks.
The proteins of interest – Aβ, tau, α-syn, and BDNF – are searched in the
STRING database, and the organism Mus musculus was selected to identify any proteinprotein interactions. The protein search led to a network view of the associations
predicted by STRING. In this view, nodes represented proteins, and colored lines
represented the evidence used to predict the interaction. The red line indicates that fusion
evidence was used for this prediction, and the green is for neighborhood evidence. Cooccurrence evidence is denoted by a blue line and experimental evidence by a purple line.
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Text mining evidence is shown with a yellow line, light blue lines indicate database
evidence, and co-expression evidence is denoted by a black line. The mode in which the
data is viewed can be changed. Confidence mode shows the user the degree of confidence
by adjusting the thickness of the evidence lines. In contrast, action mode will give
information about the predicted association type (binding, activation, etc.). The tables and
images can be exported in different formats depending on the user's preference (Starting
Point).
Statistical Analysis
Using the results from the Agilent Technologies single-color mouse (V2) gene
expression microarray, the data was transferred to Microsoft Excel for data mining. The
data was divided into two classes: Class 1 and Class 2. Class 1 samples were the control,
and those animals were not treated with ETAS®50. Class 2’s data is from mice who
received the ETAS®50 supplement. The number of genes used for random variance
estimation is 23,727, and 16,968 passed the filtering criteria. A univariate two-sample Ttest with a random variance model was used. Random variance model parameters:
a=2.49106, b=28.04457, and Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001 (Peng et al., 2021). From this data, the
geometric mean of intensities (GMOI) in class 1 and class 2 was used to determine the
fold change and quantify the effect ETAS®50 had on the protein. Fold change =
𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑖𝑖𝑖𝑖 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 2
.
𝐺𝐺𝐺𝐺𝐺𝐺𝐺𝐺 𝑖𝑖𝑖𝑖 𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 1

The protein symbol correctly identified the protein of interest when

comparing it to String Analysis data.

CHAPTER 4 – Results

Agilent Gene Microarray Data

Table 1: Agilent Gene Microarray Data

Class 1: APP; Class 2: APP+ETAS®50; Fold Change = (class 1/class2)
These genes are significant at the nominal 0.001 level of the univariate test.
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Figure 1: Collective STRING Database Data

A collective network view of all the protein interaction networks reviewed in this
study. Obtained from the STRING database (https://string-db.org/, 2021). The
organism used for this string analysis is Mus musculus. The outlined nodes
correspond to proteins related to AD pathogenesis, and the non-highlighted nodes
represent physical and functional protein interactions. Connecting the notes are
colored lines that represent the evidence database the association was collected from.
Red outline: Gene expression decreased in the presence of ETAS®50, determined by
fold change.
Green outline: Gene expression increased in the presence of ETAS®50, determined
by fold change.
Black outline: Gene expression data unknown due to not being present on the Agilent
Gene Microarray.
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Microtubule-associated protein tau (MAPT)

Figure 2: Mapt STRING network

Network View of microtubule-associated protein tau’s string interaction network.
Obtained from the STRING database (https://string-db.org/, 2021). The organism used
for this string analysis is Mus musculus. The outlined nodes correspond to proteins
related to AD pathogenesis, and the non-highlighted nodes represent physical and
functional protein interactions. Connecting the notes are colored lines that represent the
evidence database the association was collected from.
Red outline: Gene expression decreased in the presence of ETAS®50, determined by fold
change.

18

Microtubule-associated protein tau

Geometric Mean of Intensities

12000
10000

10217.45

8000
6045.5

6000

Class 1 (Not Treated w/ ETAS)

4000

Class 2 (Treated w/ ETAS)

2000
0

MAPT

Gene Symbol
Figure 3: Histogram of Mapt gene expression

Histogram of Mapt derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 0.59
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.
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Illustration 1: Role of tau in AD pathogenesis
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RB1-inducible coiled-coil 1

Figure 4: Rb1cc1 STRING network

Network View of RB1-inducible coiled-coils string interaction network. Obtained from
the STRING database (https://string-db.org/, 2021). The organism used for this string
analysis is Mus musculus. The outlined nodes correspond to proteins related to AD
pathogenesis, and the non-highlighted nodes represent physical and functional protein
interactions. Connecting the notes are colored lines that represent the evidence database
the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.

21

RB1-inducible coiled-coil 1
450

395.65

Geometric Mean of Intensities

400
350
300
250

244.63

Class 1 (Not Treated w/
ETAS)
Class 2 (Treated w/ ETAS)

200
150
100
50
0

Rb1cc1

Gene Symbol
Figure 5: Histogram of Rb1cc1 gene expression

Histogram of Rb1cc1 derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 1.62
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.
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Illustration 2: Rb1cc1’s Role in Preventing Neuronal Atrophy
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Beclin 1, autophagy-related

Figure 6: Becn1’s STRING network

Network View of beclin 1, autophagy related’s string interaction network. Obtained from
the STRING database (https://string-db.org/, 2021). The organism used for this string
analysis is Mus musculus. The outlined nodes correspond to proteins related to AD
pathogenesis, and the non-highlighted nodes represent physical and functional protein
interactions. Connecting the notes are colored lines that represent the evidence database
the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.
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Figure 7: Histogram of Becn1 gene expression

Histogram of Becn1 derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 1.53
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.

25

Illustration 3: Role of Becn1 in Apoptosis and Autophagy
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Disheveled segment polarity protein 3

Figure 8: Dvl3 STRING network

Network View of disheveled segment polarity protein 3’s string interaction network.
Obtained from the STRING database (https://string-db.org/, 2021). The organism used
for this string analysis is Mus musculus. The outlined nodes correspond to proteins
related to AD pathogenesis, and the non-highlighted nodes represent physical and
functional protein interactions. Connecting the notes are colored lines that represent the
evidence database the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.
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Figure 9: Histogram of Dvl3 gene expression

Histogram of Dvl3 derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 0.53
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.
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Illustration 4: Dvl3’s Role in Regulating Wnt Signaling via Canonical Wnt/β-catenin Pathway
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Synuclein, alpha

Figure 10: Snca STRING Network

Network View of synuclein, alpha’s string interaction network. Obtained from the
STRING database (https://string-db.org/, 2021). The organism used for this string
analysis is Mus musculus. The outlined nodes correspond to proteins related to AD
pathogenesis, and the non-highlighted nodes represent physical and functional protein
interactions. Connecting the notes are colored lines that represent the evidence database
the association was collected from.
Black outline: Gene expression data unknown due to not being present on the Agilent
Gene Microarray
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Illustration 5: Synuclein, alpha
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Heat shock protein 1A

Figure 11: Hspa1a STRING Network

Network View of heat shock protein 1A ‘s string interaction network. Obtained from the
STRING database (https://string-db.org/, 2021). The organism used for this string
analysis is Mus musculus. The outlined nodes correspond to proteins related to AD
pathogenesis, and the non-highlighted nodes represent physical and functional protein
interactions. Connecting the notes are colored lines that represent the evidence database
the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.
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Figure 12: Histogram of Hspa1a

Histogram of Hspa1a derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 2.84
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.
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DNAJ heat shock protein family (Hsp40) member B6

Figure 13: Dnajb6 STRING Network

Network View of DNAJ heat shock protein family (Hsp40) member B6’s string
interaction network. Obtained from the STRING database (https://string-db.org/, 2021).
The organism used for this string analysis is Mus musculus. The outlined nodes
correspond to proteins related to AD pathogenesis, and the non-highlighted nodes
represent physical and functional protein interactions. Connecting the notes are colored
lines that represent the evidence database the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.
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Figure 14: Histogram of Dnajb6 gene expression

Histogram of Dnajb6 derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 1.56
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.

35

Illustration 6: Role of Hspa1a and Dnajb6 in AD
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DNAJ heat shock protein family (Hsp40) member B1

Figure 15: Dnajb1 STRING Network

Network View of DNAJ heat shock protein family (Hsp40) member B1’s string
interaction network. Obtained from the STRING database (https://string-db.org/, 2021).
The organism used for this string analysis is Mus musculus. The outlined nodes
correspond to proteins related to AD pathogenesis, and the non-highlighted nodes
represent physical and functional protein interactions. Connecting the notes are colored
lines that represent the evidence database the association was collected from.
Green outline: Gene expression increased in the presence of ETAS®50, determined by
fold change.
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Figure 16: Histogram of Dnajb1 gene expression

Histogram of Hspa1a derived from the Agilent Gene Microarray data obtained from the
2021 Peng et al. experiment. This histogram depicts the geometric mean of intensities in
Class 1 and 2 samples. Class 1 samples were not treated with ETAS®50, and Class 2
samples were treated with the ETAS®50 supplement. Class 2 samples showed a 1.66
fold-change when compared to Class 1 samples. Type of univariate test used: Two
sample T-test (with random variance model). Random Variance model parameters:
a=2.49106, b=28.04457, Kolmogorov-Smirnov statistic=0.00935. The nominal
significance level of each univariate test is 0.001.
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Illustration 7: Role of Hspa1a and Dnajb1 in AD

39
Brain-derived neurotrophic factor

Figure 17: Bdnf STRING Network

Network View of brain-derived neurotrophic factor’s string interaction network.
Obtained from the STRING database (https://string-db.org/, 2021). The organism used
for this string analysis is Mus musculus. The outlined nodes correspond to proteins
related to AD pathogenesis, and the non-highlighted nodes represent physical and
functional protein interactions. Connecting the notes are colored lines that represent the
evidence database the association was collected from.
Black outline: Gene expression data unknown due to not being present on the Agilent
Gene Microarray
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Illustration 8: Bdnf’s Role in Inhibiting tau Hyperphosphorylation

41
Amyloid beta (A4) precursor protein

Figure 18: App STRING Network

Network View of amyloid beta (A4) precursor protein’s string interaction network.
Obtained from the STRING database (https://string-db.org/, 2021). The organism
used for this string analysis is Mus musculus. The outlined nodes correspond to
proteins related to AD pathogenesis, and the non-highlighted nodes represent physical
and functional protein interactions. Connecting the notes are colored lines that
represent the evidence database the association was collected from.
Black outline: Gene expression data unknown due to not being present on the Agilent
Gene Microarray
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Illustration 9: Formation of amyloid plaques from amyloid precursor protein gene

CHAPTER 5 – Discussion
Microtubule-associated protein tau (tau)
When treated with ETAS®50, there was decreased MAPT gene expression when
comparing Class 2 (treated with ETAS®50) to Class 1 (not treated with ETAS®50). A
0.59-fold decrease in MAPT gene expression is significant because aggregated tau can
lead to neurodegeneration (Muralidar et al., 2020). Under normal physiological
conditions, tau is “natively unfolded,” which plays a role in stabilizing microtubules.
Unfolded tau has a low propensity to aggregate in both intracellular and extracellular
spaces. Tau is a protein subject to several post-translational modifications such as
phosphorylation, acetylation, nitration, ubiquitination, sumoylation, truncation, and
dephosphorylation. Tau modifications can lead to the protein misfolding and
accumulating, leading to NDs. Increased tau phosphorylation leads to the aggregation of
tau proteins, a hallmark characteristic of many tauopathies. Hyperphosphorylation has the
potential to adjust the protein’s confirmation and charge, which increases tau’s propensity
to self-aggregate and oligomerize. Approximately half of the sites capable of being
phosphorylated on tau are followed by proline residues. Proline-directed protein kinases
(PDPKs) have been proven to play a role in tau phosphorylation, leading to NDs via the
early deposition of tau tangles in the brain. Non-proline-directed protein kinases (nonPDPKs) are responsible for tau phosphorylation at non-proline sites. Both PDPKs and
non-PDPKs play a role in tau phosphorylation in normal and disease-inducing conditions,
possibly leading to the pathogenesis of NDs. Tau aggregates will eventually be converted
into neurofibrillary tangles (NFTs). Before the formation of NFTs, paired helical
filaments are formed, leading to a decrease or cessation of axonal transport and
eventually destabilizing microtubules. A reduction in axonal transport and microtubule
43
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stability coupled with an increase in tau aggregates leads to misfolded tau acting as a
neurotoxin. The result of axonal transport and increased synaptic plasticity leads to the
cognitive decline noted in AD patients (Muralidar et al., 2020).
When treated with ETAS®50, there was decreased MAPT gene expression when
comparing Class 2 (treated with ETAS®50) to Class 1 (not treated with ETAS®50). A
0.59-fold decrease in MAPT gene expression is significant because aggregated tau can
lead to neurodegeneration (Muralidar et al., 2020). A reduction in the expression of the
MAPT gene reduces the changes of tau being post-translationally modified, reducing the
amount of abnormal tau being present in the body, ultimately reducing the risk of a
patient developing an ND such as AD.
RB1-inducible coiled-coil protein 1 (RB1CC1)
RB1-inducible coiled-coil protein 1 (RB1CC1) is a highly conserved protein
found in organisms such as humans, mice, rats, Caenorhabditis elegans, and others,
suggesting its function is essential. This protein is commonly known as a tumor
suppressor that regulates the expression of RB1. Still, it is suggested that RB1CC1 is
involved in neuronal atrophy and the pathogenesis of AD via the mammalian target of
rapamycin (mTOR) pathway Chano et al., 2007. The mTOR pathway regulates cell
proliferation, autophagy, and apoptosis via multiple physiological pathways (Zou et al.,
2020). RB1CC1 plays a role in the positive regulation of the mTOR pathway by inducing
tuberous sclerosis complex 1 (TSC1) degradation by ubiquitination. Acting as a TSC1
recruiter rather than a direct ubiquitin ligase, RB1CC1 assists in activating the mTOR
pathway (Chano et al., 2006). In Alzheimer’s brain tissue, RB1CC1 is transcribed less
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than in brains without AD. In RB1CC1 deficient environments, the mTOR signaling is
decreased, leading to neuronal atrophy and AD pathogenesis.
In the ETAS®50 treated mouse models, RB1CC1 gene expression was increased
1.62-fold. An abundance of RB1CC1 leads to the degradation of TSC1 (Chano et al.,
2006). The degradation of TSC1 reduces the risk of an individual being diagnosed with
AD and proves another neuroprotective effect associated with the ETAS®50 supplement
(Chano et al., 2007).
Beclin-1 (BENC1)
Beclin 1 (Becn1) encodes a protein responsible for the regulation of autophagy,
an evolutionarily conserved catabolic pathway. It plays a role in cellular processes such
as neurodegeneration, tumorigenesis, and apoptosis (Rocchi et al., 2017; Database,
Becn1). In a nutrient-rich environment, Becn1 binds to BCL2. BCL2 inhibits the
autophagic properties of Becn1. In situations of stress, Becn1 is released and is no longer
inhibited by the anti-autophagic properties of Becn1. Becn1 is a critical part of the type
III phosphatidylinositol-3-kinase (PI3K) pathway and is a necessary component to begin
autophagosome biogenesis. The hyperactivation of Becn1 has been proven to reduce the
accumulation of the Aβ protein without affecting the APP gene. Reducing the amount of
accumulated Aβ protein in the brain can possibly prevent the pathogenesis of AD (Rocchi
et al., 2017).
In the presence of ETAS®50, the expression of Becn1 was increased 1.53-fold.
An increase in Becn1 expression coincides with restoring the autophagy pathway that is
often impaired in AD patients. In addition, hyperactivation of the Becn1 gene can
significantly decrease the accumulation of Aβ protein in the brain, preventing AD
pathogenesis and cognitive decline.
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Disheveled segment polarity protein 3 (Dvl3)
Disheveled segment polarity protein 3 is a gene that encodes for the Dvl3 protein
expressed in the cytosol and has multiple highly evolutionarily conserved regions. Dvl3
is a component of the Wnt signaling pathway, and when Dvl3 is overexpressed, it
prevents the phosphorylation of tau by GSK-3β. In the canonical Wnt/β-catenin pathway,
Dvl3 is responsible for soliciting AXIN, CK1, and GSK-3β to the LRP5/6 receptor on the
cell membrane. The formation of this complex phosphorylates the LRP5/6 receptor,
which prevents β-catenin from being phosphorylated and degraded. This inhibition
mechanism allows β-catenin to bind to TCF/LEF and activate Wnt transcription. When
Wnt is absent, the destruction complex consists of APC, AXIN, CK1, and GSK-3β
phosphorylates β-catenin. β-catenin is then degraded, inhibiting Wnt transcription
(Palomer et al., 2019).
ETAS®50 decreased the expression of Dvl3 by 0.59-fold. This decrease should
be concerning for AD pathogenesis due to Dvl3’s role in preventing tau phosphorylation
via the Wnt signaling pathway; due to the decline in overall tau expression, the likelihood
of tau being phosphorylated by GSK-3β is not likely to even in the absence of β-catenin.
Synuclein, alpha
Alpha-synuclein is a 140-amino acid residue protein encoded by the synuclein,
alpha gene. This protein is expressed mainly in the neuronal presynaptic terminals and
kidney and blood cells. The function of α-syn is still not widely understood, but there
have been associations with processes in the presynaptic space. For example, it has been
reported that α-syn has a role in neuronal plasticity and learning (Twohig & Nielsen,
2019).
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In AD pathogenesis, α-syn is involved in the phosphorylation of tau by the GSk3β pathway. It is suggested that an α-syn and GSk-3β feedback loop contributes to the
aggregation of pathochemically altered proteins that lead to AD. Pathological α-syn also
can aggregate into structures called Lewy bodies that are closely associated with
dementia (Twohig & Nielsen, 2019).
Alpha-synuclein was not displayed on the gene microarray, possibly due to the
gene already being transcribed. At the time of RNA collection, the sample could not
detect any gene products, but the protein was seen in the Peng et al. experiment.
Heat shock protein 1A
Encoded by the heat shock protein 1A gene, Hspa1a is a highly evolutionarily
conserved protein that functions to re-fold proteins misfolded to prevent aggregation and
promote solubilization. In conjunction with a J domain protein, non-native proteins are
refolded through the interaction of hydrophobic residues. During cellular stress, Hsa1a
associates with misfolded protein aggregates via molecular chaperones such as Dnajb1
and Dnajb6 to associate with proteins that have been altered from their physiological
state (Mayer & Bukau, 2005).
In both wild-type and APP-overexpressing mice, the gene expression of Hsa1a
was increased. In APP-overexpressing mice, the fold change was 2.84. An increase in
wild-type and App-overexpressing indicates that ETAS®50 exhibits neuroprotective
effects in the presence and absence of neurodegeneration.
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DNAJ heat shock protein family (Hsp40) member B6
DNAJ heat shock protein family (Hsp40) member B6 is a gene that encodes the
molecular chaperone protein, Dnajb6, that associates with Hspa1a. Dnajb6 is highly
expressed in the brain and muscles. This protein aids Hspa1a in inhibiting Aβ
aggregation by binding to early-formed aggregates (Zarouchlioti et al., 2017).
The gene expression of Dnajb6 was increased 1.56-fold in the presence of
ETAS®50. An increase in the expression of Dnajb6 demonstrates the neuroprotective
effects of the asparagus supplement on the molecular chaperone.
DNAJ heat shock protein family (Hsp40) member B1
Dnajb1, a molecular chaperone protein encoded by the DNAJ heat shock protein
family (Hsp40) member B1 gene, is another protein associated with the function of
Hspa1a. Dnajb1 differs from Dnajb6 because it has been shown to reduce both tau and
Aβ aggregates by chaperoning Hspa1a to either of the misfolded proteins (Zarouchlioti et
al., 2017).
There was a 1.66-fold increase in the expression of Dnajb1 in the presence of
ETAS®50. Even when there is a decrease in the tau levels, ETAS®50 still invokes its
neuroprotective effects by increasing the levels of Dnajb1 despite downregulating tau
expression.
Brain-derived neurotrophic factor
Brain-derived neurotrophic factor is a gene that encodes for the Bdnf protein,
increasing neurons' survival and supporting neuronal differentiation and neuronal
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maturation. This neurotrophic protein that is expressed chiefly in the brain also stimulates
neurogenesis. However, in most neurodegenerative diseases, the expression of Bdnf is
often decreased (Bathina & Das, 2015).
Although not displayed on the gene microarray, it is vital to study the effects of
ETAS®50 on Bdnf because this protein already possesses neuroprotective properties. In
ND pathogenesis, this gene is downregulated. It would be a significant finding if
ETAS®50 alleviates the downregulation of Bdnf, restoring the neuroprotective effects of
Bdnf and increasing neuronal cell survival.
Amyloid beta (A4) precursor protein
The amyloid beta precursor protein is a protein-encoding gene cleaved by two
secretases to create two protein products. In the pathogenesis of AD, the Aβ peptide
product, as a result of the cleavage, is a critical player in the neurodegeneration
associated with AD once the peptide becomes misfolded and aggregates into Aβ plaques.
These plaques are hallmark characteristics of AD because they cause neuronal death, and
over time, they are responsible for the development of AD symptoms (App gene:
Medlineplus genetics 2022, Obtained from: https://medlineplus.gov/genetics/gene/app/).
Although App gene expression was not detected in the gene microarray, the
protein was seen in the Peng et al. experiment. Therefore, it is essential to understand
ETAS®50's effects directly on App, not just the reduction of the aggregates formed after
the protein is cleaved and misfolded.

CHAPTER 6 - Conclusion
ETAS®50 50 has demonstrated several neuroprotective effects in the presence of
overexpressed amyloid beta protein. The Peng et al. experiment showed the impact of
ETAS®50 on HSP70. Furthermore, analysis of the Peng et al. experiment’s Agilent gene
microarray data shed light on the possibility of ETAS®50 exhibiting neuroprotective
effects on crucial proteins associated with AD pathogenesis even after ND pathogenesis
has started.
Neuroprotective genes such as Rb1cc1, Becn1, Dnajb6, Dnajb1, and Hspa1a were
upregulated in the presence of ETAS®50. Upregulation of Rb1cc1 induced the
degradation of TSC1, a protein associated with AD pathogenesis. As a result of the
Becn1’s gene expression increase, the autophagy pathway that is impaired in the presence
of AD should be restored. Dnajb1 and Dnajb6 expressions were upregulated in mice fed
the ETAS®50 supplement, increasing the number of proteins chaperoned to Hspa1a for
refolding. An upregulation in the Hspa1a gene demonstrated neuroprotective effects by
promoting protein refolding and solubilization while preventing the aggregation of
proteins needed for AD pathogenesis.
Not all of the associated proteins researched on the Agilent gene microarray data
from the Peng et al. experiment were upregulated. Two proteins were downregulated in
the presence of ETAS®50: tau and Dvl3. Tau, a protein critical to the pathogenesis of
AD, being downregulated demonstrates a neuroprotective effect because by decreasing
the amount of tau protein found in the brain, hyperphosphorylation is less likely to occur,
reducing the risk of AD forming as a result of tau aggregates. Downregulation of Dvl3
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might initially seem negative due to its function in preventing the phosphorylation of tau,
but when tau is simultaneously being decreased, the role of Dvl3 is not heavily needed.
This experiment has demonstrated the ability of ETAS®50 to increase the effects
of neuroprotectors while decreasing neurodegenerative genes. Still, more research must
be conducted to further understand the impact of this supplement on other NDs outside of
AD. In the future, if this supplement exhibits neuroprotective effects in multiple NDs,
healthcare providers should consider using this supplement as a preventative or treatment
option for individuals prone to or living with NDs.
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